Strs Ohio Acquires 6500 Shares of Axcelis Technologies, Inc. (NASDAQ:ACLS) – Defense World
Posted by admin on Jul 13th, 2022 
Strs Ohio raised its holdings in shares of Axcelis Technologies, Inc. (NASDAQ:ACLS – Get Rating) by 59.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,400 shares of the semiconductor company’s stock after purchasing an additional 6,500 shares during the period. Strs Ohio’s holdings in Axcelis Technologies were worth $1,314,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in ACLS. Private Capital Group LLC bought a new position in Axcelis Technologies during the 1st quarter valued at approximately $33,000. CWM LLC raised its position in Axcelis Technologies by 57.7% during the 1st quarter. CWM LLC now owns 514 shares of the semiconductor company’s stock valued at $39,000 after purchasing an additional 188 shares during the last quarter. Covestor Ltd bought a new position in Axcelis Technologies during the 4th quarter valued at approximately $56,000. Maverick Capital Ltd. bought a new position in Axcelis Technologies during the 4th quarter valued at approximately $145,000. Finally, Optimum Investment Advisors purchased a new position in shares of Axcelis Technologies during the 1st quarter worth approximately $177,000. 83.38% of the stock is owned by institutional investors and hedge funds.
ACLS stock opened at $52.70 on Wednesday. Axcelis Technologies, Inc. has a fifty-two week low of $33.36 and a fifty-two week high of $83.74. The business’s 50 day moving average price is $56.30 and its two-hundred day moving average price is $62.83. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.02 and a current ratio of 4.40. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of 14.52 and a beta of 1.65.
Axcelis Technologies (NASDAQ:ACLS – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The semiconductor company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.30. The company had revenue of $203.60 million for the quarter, compared to the consensus estimate of $193.12 million. Axcelis Technologies had a return on equity of 23.53% and a net margin of 16.88%. The firm’s quarterly revenue was up 53.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.48 EPS. Sell-side analysts forecast that Axcelis Technologies, Inc. will post 4.4 earnings per share for the current year.
A number of research analysts have weighed in on the company. StockNews.com upgraded Axcelis Technologies from a “buy” rating to a “strong-buy” rating in a report on Friday, July 8th. B. Riley reduced their target price on Axcelis Technologies from $98.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, June 15th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $75.75.
About Axcelis Technologies (Get Rating)
Axcelis Technologies, Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia. The company offers high energy, high current, and medium current implanters for various application requirements.
Featured Stories
Want to see what other hedge funds are holding ACLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axcelis Technologies, Inc. (NASDAQ:ACLS – Get Rating).
Receive News & Ratings for Axcelis Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axcelis Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
Brian Mueller Sells 7,337 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock
Tarbox Family Office Inc. Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)